BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 17, 2003
 |  BioCentury  |  Product Development

Kineret won't combine with Enbrel

It appears that Amgen Inc.'s hopes for a label combining TNF alpha inhibitors such as its Enbrel etanercept with its Kineret anakinra to treat rheumatoid arthritis have been dashed. The company's trial of the combination showed that administration of Enbrel with Kineret provided no therapeutic benefit and resulted in an increased incidence of serious infection and neutropenia compared with Enbrel alone. As a result, the EMEA has issued a warning of safety concerns related to...

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >